Amarin Corporation plc (AMRN)
Stock · NASDAQ · Health Care
$11.32as of 10/16/2026
Price chart
Active signals
AMRN Signal Track Record
How signals performed across all stocks →What AMRN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 43 | -4.9% | 35% | September 25, 2026 |
| Bollinger Band Breakout | 25 | -5.4% | 36% | June 12, 2026 |
| Bollinger Band Breakdown | 20 | -3.2% | 25% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -5.6% | 30% | July 7, 2026 |
| Any 20-session window (baseline) | -2.4% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 80
- Website
- amarincorp.com/
Fundamentals
- 1-day range
- $11.25$11.58
- Market cap
- $301.21M
- P/E (trailing)
- —
- P/E (forward)
- 11.55
- EPS (trailing)
- $-0.07
- Dividend yield
- —
- Beta
- 0.77
- Avg. volume
- 65.6K
How Amarin Corporation plc Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Amarin Corporation plc Competitors
Chosen by industry and closest market cap.
- AMRNAmarin Corporation plc$11.32▼ 2.16%Market cap $301.21MP/E —$11.34$20.9
- IRDOpus Genetics Inc. Common Stock$3.84▼ 5.19%Market cap $307.14MP/E —$1.7$7.07
- VNDAVanda Pharmaceuticals Inc. Common Stock$4.03▼ 4.95%Market cap $307.59MP/E —$4.27$9.94
- ORGOOrganogenesis Holdings Inc. Class A Common Stock$1▼ 9.91%Market cap $310.11MP/E 84.95$1.13$7.08
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
- FULCFulcrum Therapeutics Inc. Common Stock$3.65▼ 0.54%Market cap $287.64MP/E —$2.83$15.74
- TTRXTurn Therapeutics Inc. Common Stock$10.57▼ 8.80%Market cap $286.26MP/E —$2.57$26.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AMRN Amarin Corporation plc | $301.21M | — | $11.32 | ▼ 2.16% | $11.34$20.9 |
| IRD Opus Genetics Inc. Common Stock | $307.14M | — | $3.84 | ▼ 5.19% | $1.7$7.07 |
| VNDA Vanda Pharmaceuticals Inc. Common Stock | $307.59M | — | $4.03 | ▼ 4.95% | $4.27$9.94 |
| ORGO Organogenesis Holdings Inc. Class A Common Stock | $310.11M | 84.95 | $1 | ▼ 9.91% | $1.13$7.08 |
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
| FULC Fulcrum Therapeutics Inc. Common Stock | $287.64M | — | $3.65 | ▼ 0.54% | $2.83$15.74 |
| TTRX Turn Therapeutics Inc. Common Stock | $286.26M | — | $10.57 | ▼ 8.80% | $2.57$26.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyYahoo · 10/1/2026
- Teva's Branded Drugs Take Center Stage in Its Growth StrategyYahoo · 9/29/2026
- RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma StudyYahoo · 9/17/2026
- RCKT Aligns With FDA on Completing Phase II Study in Danon DiseaseYahoo · 9/16/2026
Insider Activity
Insider Actions →- Peter L. Fishman · August 1, 2026 · Grant313
- Peter L. Fishman · August 1, 2026 · Tax Withholding155 @ $14.26
- Peter L. Fishman · August 1, 2026 · Option Exercise313
- Steven B. Ketchum · July 1, 2026 · Tax Withholding1.9K @ $15.94
- Steven B. Ketchum · July 1, 2026 · Option Exercise3.7K
- David Paul Keenan · July 1, 2026 · Grant3.7K
- David Paul Keenan · July 1, 2026 · Tax Withholding1.9K @ $15.94
- David Paul Keenan · July 1, 2026 · Option Exercise3.7K
- Peter L. Fishman · July 1, 2026 · Grant2.4K
- Peter L. Fishman · July 1, 2026 · Tax Withholding1.2K @ $15.94
- Peter L. Fishman · July 1, 2026 · Option Exercise2.4K
- Jonathan Provoost · July 1, 2026 · Grant3.7K
- Jonathan Provoost · July 1, 2026 · Tax Withholding1.3K @ $15.94
- Jonathan Provoost · July 1, 2026 · Option Exercise3.7K
- Steven B. Ketchum · July 1, 2026 · Grant3.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 4.67M
- Total value held
- $58.07M
- Institutional holders
- 65
- Unknown1.67M
- Unknown636.8K
- Unknown472.4K
- Unknown300.5K
- Unknown293.2K
- Unknown240.8K
- Unknown203.3K
- Unknown147.7K
- Unknown107.5K
- Unknown95.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Amarin (AMRN) sees competition as Teva pushes branded drugs
Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.
Amarin (AMRN) sees competition as Teva pushes branded drugs. Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.